Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) Sees Large Drop in Short Interest

Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) saw a large decline in short interest in the month of March. As of March 31st, there was short interest totalling 74,500 shares, a decline of 55.0% from the March 15th total of 165,500 shares. Based on an average daily trading volume, of 1,140,000 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.3% of the company’s shares are short sold.

Inspira Technologies Oxy B.H.N. Price Performance

Shares of Inspira Technologies Oxy B.H.N. stock traded up $0.01 during trading on Wednesday, hitting $0.62. 397,886 shares of the stock were exchanged, compared to its average volume of 408,041. The company has a fifty day moving average price of $0.76 and a 200-day moving average price of $1.05. Inspira Technologies Oxy B.H.N. has a 1-year low of $0.54 and a 1-year high of $2.45. The company has a quick ratio of 2.13, a current ratio of 2.23 and a debt-to-equity ratio of 0.09.

Institutional Investors Weigh In On Inspira Technologies Oxy B.H.N.

A hedge fund recently raised its stake in Inspira Technologies Oxy B.H.N. stock. Renaissance Technologies LLC increased its position in Inspira Technologies Oxy B.H.N. Ltd. (NASDAQ:IINN) by 142.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 36,622 shares of the company’s stock after buying an additional 21,532 shares during the quarter. Renaissance Technologies LLC owned 0.29% of Inspira Technologies Oxy B.H.N. worth $37,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 12.72% of the stock is owned by institutional investors and hedge funds.

Inspira Technologies Oxy B.H.N. Company Profile

Inspira Technologies Oxy B.H.N. Ltd., a specialty medical device company, engages in the research, development, manufacture, and marketing of respiratory support technology to provide an alternative to invasive mechanical ventilation for the treatment of acute respiratory failure. Its lead product is the augmented respiration technology system, a respiratory support system comprising minimally invasive, portable dual lumen cannula, which is inserted into the jugular vein and utilizes extra-corporeal direct blood oxygenation to elevate and stabilize declining oxygen saturation levels.